Mersana Therapeutics (MRSN) Misses Q3 EPS by 137c
Tweet
Share
E-mailGet Alerts MRSN Hot Sheet
Join SI Premium – FREE
Mersana Therapeutics (NASDAQ: MRSN) reported Q3 EPS of ($1.51), $1.37 worse than the analyst estimate of ($0.14). Revenue for the quarter came in at $11 million versus the consensus estimate of $6.35 million.
For earnings history and earnings-related data on Mersana Therapeutics (MRSN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
- RBC Capital Downgrades CareTrust REIT (CTRE) to Sector Perform
- Macquarie Upgrades DiDi Global (DIDIY) to Outperform
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
